Cargando…

Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia

Detalles Bibliográficos
Autores principales:	Bewersdorf, Jan Philipp, Patel, Kishan K., Huntington, Scott F., Zeidan, Amer M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759135/ https://www.ncbi.nlm.nih.gov/pubmed/34525174 http://dx.doi.org/10.1182/bloodadvances.2021005472

Ejemplares similares

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Hyperleukocytosis and Leukostasis in Acute Myeloid Leukemia: Can a Better Understanding of the Underlying Molecular Pathophysiology Lead to Novel Treatments?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy
por: Kara, Asude, et al.
Publicado: (2017)

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Hard-wired biases in trials: maintenance azacitidine in patients with acute myeloid leukemia and framework for future trials
por: Olivier, Timothée, et al.
Publicado: (2022)

Subcutaneous azacitidine maintenance in transplant-ineligible patients with acute myeloid leukemia: a single-center retrospective study
por: Johnson, Natacha, et al.
Publicado: (2023)

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
por: Roboz, Gail J, et al.
Publicado: (2016)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia with NUP98-RARG Gene Fusion
por: Yuan, Jiaojiao, et al.
Publicado: (2023)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Shallis, Rory M., et al.
Publicado: (2021)

Maintenance therapy with alternating azacitidine and lenalidomide in elderly fit patients with poor prognosis acute myeloid leukemia: a phase II multicentre FILO trial
por: Hunault-Berger, M, et al.
Publicado: (2017)

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial
por: Wei, Andrew H., et al.
Publicado: (2023)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

P587: REAL-WORLD CHARACTERISTICS AND USE OF ANTIEMETIC THERAPIES AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ORAL AZACITIDINE MAINTENANCE THERAPY
por: Qiu, Ying, et al.
Publicado: (2023)

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
por: DiNardo, Courtney D., et al.
Publicado: (2021)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Azacitidine as Salvage Therapy for Acute Myeloid Leukemia in a Severely Ill Patient
por: Powers, Harry Ross, et al.
Publicado: (2014)

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
por: Shapiro, Roman M., et al.
Publicado: (2018)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Azacitidine-Induced Pneumonitis in a Patient With Acute Myeloid Leukemia and Hyperleukocytosis
por: Litvin, Rafaella, et al.
Publicado: (2022)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

PB1885: PHASE 1 STUDY OF ZIFTOMENIB IN COMBINATION WITH VENETOCLAX, VENETOCLAX/AZACITIDINE, OR STANDARD INDUCTION (7 + 3) CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Zeidan, Amer M, et al.
Publicado: (2023)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia
por: Dumas, Pierre-Yves, et al.
Publicado: (2017)

Gilteritinib Combined with Azacitidine as Salvage Therapy for B/Myeloid Mixed Phenotype Acute Leukemia
por: Horvat, Nathan P, et al.
Publicado: (2022)

Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis
por: Guinan, Kimberly, et al.
Publicado: (2022)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
por: Hollenbach, Paul W., et al.
Publicado: (2010)

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine
por: Bories, Pierre, et al.
Publicado: (2020)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
por: Zeidan, Amer M., et al.
Publicado: (2023)

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
por: Pleyer, Lisa, et al.
Publicado: (2014)

A Case of Recurrent Ovarian Cancer and Therapy-Related Acute Myeloid Leukemia Treated with Azacitidine
por: Ando, Kenju, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m53bo2t2ph7be3ib2kflbe6256